Cite
Healy D, Bahrick A, Bak M, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2021;doi: 10.3233/JRS-210023.
Healy, D., Bahrick, A., Bak, M., Barbato, A., Calabrò, R. S., Chubak, B. M., Cosci, F., Csoka, A. B., D'Avanzo, B., Diviccaro, S., Giatti, S., Goldstein, I., Graf, H., Hellstrom, W. J. G., Irwig, M. S., Jannini, E. A., Janssen, P. K. C., Khera, M., Kumar, M. T., Le Noury, J., Lew-Starowicz, M., Linden, D. E. J., Lüning, C., Mangin, D., Melcangi, R. C., Rodríguez, O. W. M. A. A. S., Panicker, J. N., Patacchini, A., Pearlman, A. M., Pukall, C. F., Raj, S., Reisman, Y., Rubin, R. S., Schreiber, R., Shipko, S., Vašečková, B., & Waraich, A. (2021). Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. The International journal of risk & safety in medicine, . https://doi.org/10.3233/JRS-210023
Healy, David, et al. "Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin." The International journal of risk & safety in medicine vol. (2021). doi: https://doi.org/10.3233/JRS-210023
Healy D, Bahrick A, Bak M, Barbato A, Calabrò RS, Chubak BM, Cosci F, Csoka AB, D'Avanzo B, Diviccaro S, Giatti S, Goldstein I, Graf H, Hellstrom WJG, Irwig MS, Jannini EA, Janssen PKC, Khera M, Kumar MT, Le Noury J, Lew-Starowicz M, Linden DEJ, Lüning C, Mangin D, Melcangi RC, Rodríguez OWMAAS, Panicker JN, Patacchini A, Pearlman AM, Pukall CF, Raj S, Reisman Y, Rubin RS, Schreiber R, Shipko S, Vašečková B, Waraich A. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2021 Oct 26; doi: 10.3233/JRS-210023. Epub 2021 Oct 26. PMID: 34719438.
Copy
Download .nbib